ID: ALA3958704

Max Phase: Preclinical

Molecular Formula: C26H27NO5

Molecular Weight: 433.50

Molecule Type: Small molecule

Representations

Canonical SMILES:  C/C(=C\COc1ccccc1CN(C)C(=O)c1ccc(-c2ccco2)cc1)CCC(=O)O

Standard InChI:  InChI=1S/C26H27NO5/c1-19(9-14-25(28)29)15-17-32-24-7-4-3-6-22(24)18-27(2)26(30)21-12-10-20(11-13-21)23-8-5-16-31-23/h3-8,10-13,15-16H,9,14,17-18H2,1-2H3,(H,28,29)/b19-15+

Standard InChI Key:  WZFMWAHUFRLQRH-XDJHFCHBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 433.50

Molecular Weight (Monoisotopic): 433.1889

AlogP: 5.41

#Rotatable Bonds: 10

Polar Surface Area: 79.98

Molecular Species: ACID

HBA: 4

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 4.12

CX Basic pKa:

CX LogP: 4.48

CX LogD: 1.39

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.43

Np Likeness Score: -0.51

References

1. Blass B..  (2016)  PPAR Agonists, Compounds, Pharmaceutical Compositions, and Methods of Use Thereof.,  7  (9): [PMID:27660684] [10.1021/acsmedchemlett.6b00301]

2. Lagu B, Kluge AF, Fredenburg RA, Tozzo E, Senaiar RS, Jaleel M, Panigrahi SK, Tiwari NK, Krishnamurthy NR, Takahashi T, Patane MA..  (2017)  Novel highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulators with pharmacokinetic properties suitable for once-daily oral dosing.,  27  (23): [PMID:29103972] [10.1016/j.bmcl.2017.10.037]

3. Lagu B, Kluge AF, Goddeeris MM, Tozzo E, Fredenburg RA, Chellur S, Senaiar RS, Jaleel M, Babu DRK, Tiwari NK, Takahashi T, Patane MA..  (2018)  Highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulator demonstrates improved safety profile compared to GW501516.,  28  (3): [PMID:29275935] [10.1016/j.bmcl.2017.11.006]

4. Lagu B, Senaiar RS, Kluge AF, Mallesh B, Ramakrishna M, Bhat R, Patane MA..  (2020)  Addressing hERG activity while maintaining favorable potency, selectivity and pharmacokinetic properties of PPARδ modulators.,  30  (4): [PMID:31889664] [10.1016/j.bmcl.2019.126928]

5. Lagu B,Kluge AF,Tozzo E,Fredenburg R,Bell EL,Goddeeris MM,Dwyer P,Basinski A,Senaiar RS,Jaleel M,Tiwari NK,Panigrahi SK,Krishnamurthy NR,Takahashi T,Patane MA.  (2018)  Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD).,  9  (9.0): [PMID:30258544] [10.1021/acsmedchemlett.8b00287]

Source

Source(1):

• Scientific Literature